VLA.AX - Viralytics Limited

ASX - ASX Delayed Price. Currency in AUD

Viralytics Limited

66 Hunter Street
Suite 305 Level 3
Sydney, NSW 2000
61 2 9988 4000

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Malcolm L. McColl BVSc (Hons), MBAMD, CEO & Exec. Director564.28kN/AN/A
Mr. Robert VickeryChief Financial Officer198.12kN/AN/A
Prof. Darren Shafren B.Sc (Hons I) Ph.D.Chief Scientific Officer364.7kN/AN/A
Dr. Jennifer Rosenthal Ph.D.Director of Regulatory Affairs237.75kN/AN/A
Ms. Rae SaltzsteinDirector of CMC Operations66.01kN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

Corporate Governance

Viralytics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.